Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

Erythropoiesis stimulating agent (ESA) treatment failure is associated with poor prognosis for patients with IPSS[1][1] low and intermediate-1 (‘lower risk’) myelodysplastic syndromes (MDS)[2][2] and, to date, there is no standard treatment option. In this subgroup of patients, disease modifying